Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

317 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
First- and second-line therapy of metastatic colorectal cancer.
Terstriep S, Grothey A. Terstriep S, et al. Among authors: grothey a. Expert Rev Anticancer Ther. 2006 Jun;6(6):921-30. doi: 10.1586/14737140.6.6.921. Expert Rev Anticancer Ther. 2006. PMID: 16761936 Review.
Chemotherapy for advanced gastric cancer.
Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE. Wagner AD, et al. Among authors: grothey a. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004064. doi: 10.1002/14651858.CD004064.pub2. Cochrane Database Syst Rev. 2005. PMID: 15846694 Updated. Review.
A third investigator was consulted in case of disagreements. We contacted study authors to obtain missing information. MAIN RESULTS: Chemotherapy versus best supportive care consistently demonstrated a significant benefit in terms of overall survival in favour of th
A third investigator was consulted in case of disagreements. We contacted study authors to obtain missing information. MAIN RESULTS:
Chemotherapy in elderly patients with colorectal cancer.
Köhne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Köhne CH, et al. Among authors: grothey a. Ann Oncol. 2001 Apr;12(4):435-42. doi: 10.1023/a:1011170808734. Ann Oncol. 2001. PMID: 11398873 Review.
With a continuous increase in life expectancy we may expect a higher number of elderly patients in the future. Because patients above 70 or 75 years are often excluded there is uncertainty as to what extent systemic adjuvant and palliative treatment should be offere …
With a continuous increase in life expectancy we may expect a higher number of elderly patients in the future. Because patient …
New chemotherapy approaches in colorectal cancer.
Grothey A, Schmoll HJ. Grothey A, et al. Curr Opin Oncol. 2001 Jul;13(4):275-86. doi: 10.1097/00001622-200107000-00011. Curr Opin Oncol. 2001. PMID: 11429486 Review.
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. Goetz MP, et al. Among authors: grothey aa. Invest New Drugs. 2013 Dec;31(6):1559-67. doi: 10.1007/s10637-013-0034-9. Epub 2013 Oct 10. Invest New Drugs. 2013. PMID: 24114122 Free PMC article. Clinical Trial.
PURPOSE: We performed a UGT1A1 genotype-guided study to determine the maximum tolerated dose (MTD) and evaluate the toxicities and pharmacokinetics of the combination of capecitabine (CAP), oxaliplatin (OX), and irinotecan (IRIN). ...UGT1A1 *28/*28 patients (n = 3) treated …
PURPOSE: We performed a UGT1A1 genotype-guided study to determine the maximum tolerated dose (MTD) and evaluate the toxicities and ph …
A new chemoembolization protocol in refractory liver metastasis of colorectal cancer--a feasibility study.
Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ. Voigt W, et al. Among authors: grothey a. Onkologie. 2002 Apr;25(2):158-64. doi: 10.1159/000055226. Onkologie. 2002. PMID: 12006767
PATIENTS AND METHODS: The following protocol was applied via a selective transfemoral hepatic arterial approach: mitomycin C 5 mg/m(2), interferon-alpha2b 4.5 Mio IU, dexamethasone 20 mg mixed with Amilomer DSM 45/25 (Spherex((R))) days 1 and 2 i.a. (bolus), oxalipl …
PATIENTS AND METHODS: The following protocol was applied via a selective transfemoral hepatic arterial approach: mitomycin C 5 mg/m(2 …
Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S. Wagner AD, et al. Among authors: grothey aa. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005392. doi: 10.1002/14651858.CD005392.pub3. Cochrane Database Syst Rev. 2009. PMID: 19588372 Review.
DATA COLLECTION AND ANALYSIS: Data collection and analysis was performed, according to a previously published protocol. Because individual patient data was not provided, aggregate data had to be used for the analysis. ...For second-line chemotherapy, with or without bevaci …
DATA COLLECTION AND ANALYSIS: Data collection and analysis was performed, according to a previously published protocol. Because indiv …
Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A; ARIES Study Investigators. Hurwitz HI, et al. Among authors: grothey a. Clin Oncol (R Coll Radiol). 2014 Jun;26(6):323-32. doi: 10.1016/j.clon.2014.03.001. Epub 2014 Mar 28. Clin Oncol (R Coll Radiol). 2014. PMID: 24686090
AIMS: The Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study (OCS) was designed to prospectively examine outcomes associated with bevacizumab-containing treatment for metastatic colorectal cancer (mCRC) in a community-based s …
AIMS: The Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study (OCS) was designed to prospecti …
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A; Adjuvant Colon Cancer End-points (ACCENT) Group. Sargent D, et al. Among authors: grothey a. Eur J Cancer. 2011 May;47(7):990-6. doi: 10.1016/j.ejca.2010.12.015. Epub 2011 Jan 21. Eur J Cancer. 2011. PMID: 21257306 Free PMC article.
ACCENT further proposed (1) a stronger association between DFS and OS in stage III than II, and (2) 6 or 7 years necessary to demonstrate DFS/OS surrogacy in recent trials. ...
ACCENT further proposed (1) a stronger association between DFS and OS in stage III than II, and (2) 6 or 7 years necessary to demonst …
Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH. Hochster HS, et al. Among authors: grothey a. Ann Oncol. 2014 Jun;25(6):1172-8. doi: 10.1093/annonc/mdu107. Epub 2014 Mar 7. Ann Oncol. 2014. PMID: 24608198 Free PMC article. Clinical Trial.
Tumor response was not a study end point. Given DMC concerns, an additional independent, blinded radiology review of all images showed no adverse effect of treatment schedule or Ca/Mg on response by Response Evaluation Criteria In Solid Tumors. ...CONCLUSIONS: An IO dosing …
Tumor response was not a study end point. Given DMC concerns, an additional independent, blinded radiology review of all images showe …
317 results
Jump to page
Feedback